New drug STP938 tested in patients with incurable cancers

NCT ID NCT06297525

Recruiting now Disease control Sponsor: Step Pharma, SAS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special group for patients with a specific type of ovarian cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Comprehensive Hematology Oncology, LLC
RECRUITING

St. Petersburg, Florida, 33709, United States
Institut Gustave Roussy
RECRUITING

Villejuif, Paris, 94805, France
Mary Crowley Cancer Research Center
RECRUITING

Dallas, Texas, 75251, United States
Next Oncology
RECRUITING

San Antonio, Texas, 78292, United States
The Beatson Institute for Cancer Research
RECRUITING

Glasgow, Glasgow, G12 8QQ, United Kingdom
The Christie
RECRUITING

Manchester, M20 4BX, United Kingdom
University College London
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.